BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. META

Go back to BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook

BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $105 at Leerink Partners

October 30, 2024 6:26 AM EDT

Leerink Partners analyst Joseph Schwartz lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $105.00 (from $132.00) while maintaining a Outperform rating.

The analyst comments "Bottom Line: This time last year on the 3Q23 earnings conference call, former CEO Jean Jacques (JJ) Bienaimé publicized his retirement (effective December 1, 2023) and Alexander Hardy who was the CEO of Genentech at Roche (RHHBY, Not Rated) at... More